Acme United’s Record 2025 Strengthens Long-Term Outlook; Buy Rating Reaffirmed

In 2025, Acme United Corporation (US: ACU – $43.41) delivered record sales and earnings, achieving the strongest financial performance in its history despite a year marked by volatility and uncertainty. The Company navigated tariff disruptions, shifting customer demand, and global supply chain challenges to produce improved results across most of its key metrics.

Several initiatives strengthened the Company’s long-term competitive position in 2025. The first aid division introduced the RFID SmartCompliance Cabinet at the 2025 NSC Safety Congress & Expo. The RFID system is a patented automatic replenishment system that uses sensors to detect depleted or obsolete components in industrial first aid kits and that automatically generates refill orders. Customers typically save between 30% and 50% compared to traditional van-based delivery systems.

The Westcott brand expanded market share in cutting tools, particularly in the craft segment, leveraging patented nonstick technology to create differentiated products designed for cutting adhesive materials. The Company also grew its line of ceramic safety tools and increased sales of industrial cutting tools.

Investments in robotics at three U.S. based sites improved assembly efficiency and quality for first aid refill products. The Company also implemented new warehouse optimization software at its facility in Rocky Mount, streamlined inventory processes, and deployed drones for nightly inventory reconciliation.

In addition to the Tennessee facility acquisition, the Company purchased new automated processing equipment to support the expansion of its Spill Magic, bodily fluid kit, and blood-borne pathogen product lines.

Finally, in January 2026, the Company acquired My Medic, a leading direct-to-consumer supplier of advanced first aid and bleed control products in the United States. My Medic generated approximately $19 million in revenue in 2025 and was acquired for $18.7 million. With more than 500,000 social media followers, the brand provided a strong platform for expanded product offerings and distribution in the U.S. and Canada.

Management emphasized that the Company exited 2025 with a strong balance sheet and continued to benefit from investments in distribution capacity, productivity improvements, and cost reduction initiatives. It continued to invest in advanced production equipment at its Med-Nap facility in Brooksville, Florida, expanded its quality assurance capabilities, and prepared to become a significant domestic supplier to the broader U.S. medical market.

As the Company moves into 2026, it expects growth in its first aid and medical segments and a normalization of retail merchandising and promotional activity. With expanded domestic production and diversified international sourcing, the Company believes it is well positioned for continued growth, both organically and through acquisitions.

We reiterate our buy recommendation for Acme United Corp. with a price target of $53.47 for 2026, which is 23% above today’s stock price.

Smallcaps.us Advice: Buy	Price Target: $53.47	Latest Company Report (pdf)
For important disclosures, please read our disclaimer.